PlainPharmaWatch

CMS Open Payments · Tool

Tris Pharma Inc vs IBSA Institut Biochimique SA

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

IBSA Institut Biochimique SA has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,512, versus 83 for the other company. Its single largest recorded recipient represents 0.4% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Tris Pharma Inc
HHI 83 · top recipient 0.1%
Ranked #1,717 of 1,838 companies by HHI
IBSA Institut Biochimique SA
HHI 2,512 · top recipient 0.4%
Ranked #644 of 1,838 companies by HHI

Payment Overview

Company A

Tris Pharma Inc

Total Payments
$11.4M
% of Industry
0.1%
Transactions
23,743
Avg per Transaction
$478.14
Recipients
23,649
Avg per Recipient
$480.04
Payment Types
6
Top Payment Type
Food and Beverage
Total Payments
$11.4M
% of Industry
0.1%
Transactions
371
Avg per Transaction
$30.8K
Recipients
17
Avg per Recipient
$671.1K
Payment Types
5
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Tris Pharma Inc vs IBSA Institut Biochimique SA - total reported payments in CMS Open Payments PY2024

IBSA Institut Biochimique SA$11.4MTris Pharma Inc$11.4M

Payment Types Breakdown

Tris Pharma Inc

Food and Beverage $470.7K

4.1%

Honoraria $187.7K

1.7%

Consulting Fee $58.3K

0.5%

Travel and Lodging $23.8K

0.2%

Compensation for Services Other Than Consulting $1.5K

0.0%

Education $627.90

0.0%

IBSA Institut Biochimique SA

Consulting Fee $41.2K

0.4%

Compensation for Services Other Than Consulting $4.0K

0.0%

Travel and Lodging $3.5K

0.0%

Grant $1.3K

0.0%

Food and Beverage $32.00

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Tris Pharma Inc

  1. 1

    MICHAEL FELD

    $42,949.49 · 82 txns

  2. 2

    JEFFREY GUDIN

    $25,770.06 · 15 txns

  3. 3

    CHARLES ARGOFF

    $16,470.41 · 3 txns

  4. 4

    ANN CHILDRESS

    $12,337.11 · 10 txns

  5. 5

    JOEL YOUNG

    $12,070.70 · 12 txns

IBSA Institut Biochimique SA

  1. 1

    ZBIGNIEW PAUL LORENC

    $20,000.00 · 2 txns

  2. 2

    HEMA A. SUNDARAM

    $13,000.00 · 3 txns

  3. 3

    JAMES TONER

    $4,857.80 · 2 txns

  4. 4

    MICHAEL HOWARD GOLD

    $4,000.00 · 1 txns

  5. 5

    VALERIE LYNN BAKER

    $2,815.75 · 2 txns

Summary Comparison

Metric Tris Pharma Inc IBSA Institut Biochimique SA
Total Payments $11.4M $11.4M
% of Industry Total 0.1% 0.1%
Transaction Count 23,743 371
Avg per Transaction $478.14 $30.8K
Recipient Count 23,649 17
Avg per Recipient $480.04 $671.1K
Payment Type Count 6 5
Top Payment Type Food and Beverage Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.